A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01510561
Recruitment Status : Unknown
Verified February 2015 by Immunomedics, Inc..
Recruitment status was:  Active, not recruiting
First Posted : January 16, 2012
Last Update Posted : February 16, 2015
Information provided by (Responsible Party):
Immunomedics, Inc.